https://www.selleckchem.com/products/bufalin.html
Nonalcoholic fatty liver disease (NAFLD) is an obesity-related comorbidity, and it is characterized as a spectrum of liver abnormalities, including inflammation, steatosis, and fibrosis. The gut-liver axis is implicated in the pathogenesis and development of NAFLD. A promising drug agent targeting the gut-liver axis is expected to reverse NAFLD. We utilized high-fat diet (HFD)-induced obese mice and obesity-prone Lep mice to examine the gut-liver regulation of the natural medicine Panax Notoginseng Saponins (PNS) on NAFLD. PNS exhibited
Gefällt mir
Kommentar
Teilen
